Ro vs Henry Meds 2026: GLP-1 Weight Loss Programs Compared

Ro vs Henry Meds vs Trimi: Full Comparison Table

This comparison covers the factors patients report caring about most. All pricing reflects data observed as of early 2026 and may change. Always verify current pricing directly with each provider.

Pricing Deep Dive: Total Cost of Treatment

Price is the most searched factor in the Ro vs Henry Meds comparison, and the differences are more significant than they first appear. The total cost of GLP-1 treatment extends beyond the advertised monthly medication price to include consultation fees, dose escalation costs, and any contractual commitments that lock in multi-month spending.

Ro Pricing Breakdown

Ro charges approximately $99 to $199 per month for compounded semaglutide, with the range depending on your current dose tier as you progress through the standard escalation protocol. For compounded tirzepatide, Ro pricing ranges from $199 to $349 per month. Most Ro plans include the consultation fee in the monthly price, which simplifies cost tracking. Some plans require a 3-month commitment for the lowest advertised rate. Over a typical 6-month treatment course on semaglutide, a Ro patient might spend between $594 and $1,194 in total medication costs.

Henry Meds Pricing Breakdown

Henry Meds charges $199 to $349 per month for compounded semaglutide and $299 to $449 per month for compounded tirzepatide. Crucially, Henry Meds adds a separate consultation fee of $49 to $99 on top of the monthly medication price. This consultation fee applies at enrollment and may recur at follow-up intervals. Over a 6-month semaglutide course, a Henry Meds patient might spend between $1,243 and $2,193 when including consultation fees. This makes Henry Meds the more expensive option in a head-to-head comparison with Ro for most patients.

Trimi Pricing Comparison

For context, Trimi offers compounded semaglutide at $99 per month and compounded tirzepatide at $125 per month. All consultations, provider check-ins, and ongoing clinical support are included in those prices with no separate fees. No contracts are required. Over a 6-month semaglutide course, total Trimi cost is $594 — less than half what a Henry Meds patient would pay for comparable treatment. For patients researching the cheapest GLP-1 injections in 2026, the pricing gap between providers is substantial.

Medications: Semaglutide and Tirzepatide Access

Both Ro and Henry Meds offer compounded versions of the two most clinically validated GLP-1 medications for weight loss: semaglutide and tirzepatide. These are not the brand-name formulations (Wegovy and Zepbound) but compounded equivalents produced by 503B-registered pharmacies under FDA oversight. The active pharmaceutical ingredient is the same, though compounded formulations may differ in concentration, excipients, and delivery device.

Semaglutide is a GLP-1 receptor agonist that demonstrated 14.9 percent mean body weight loss in the STEP 1 trial involving 1,961 participants over 68 weeks (Wilding et al., New England Journal of Medicine, 2021). Tirzepatide is a dual GIP/GLP-1 receptor agonist that demonstrated even greater efficacy, with participants losing up to 22.5 percent of body weight at the highest dose in the SURMOUNT-1 trial involving 2,539 participants (Jastreboff et al., New England Journal of Medicine, 2022). Both medications work by reducing appetite, slowing gastric emptying, and improving metabolic signaling.

Ro's access to tirzepatide has historically been more consistent than Henry Meds, likely because Ro Pharmacy's vertical integration provides better supply chain control. Henry Meds relies on third-party pharmacy partners, which can introduce variability in tirzepatide availability depending on raw material supply and compounding capacity. For patients who specifically want tirzepatide treatment, confirming current availability before enrolling with any provider is advisable.

Trimi offers both compounded semaglutide and compounded tirzepatide with consistent nationwide availability through PCAB-accredited pharmacy partners. Patients switching from either Ro or Henry Meds can transfer their current dose without restarting the titration process.

Provider Model: How Clinical Care Differs

The provider model is where the difference between a generalist telehealth platform and a specialized weight management clinic becomes most apparent. Both Ro and Henry Meds use telehealth consultations to evaluate patients and prescribe GLP-1 medications, but the depth and focus of that clinical interaction varies significantly.

Ro's Provider Approach

Ro uses a network of licensed physicians and nurse practitioners who handle consultations across multiple health categories. The initial evaluation is typically asynchronous — patients complete a medical questionnaire, and a provider reviews it and makes a prescribing decision. Ro also offers optional video consultations for patients who want face-to-face interaction. Ongoing support is primarily messaging-based. The strength of this model is accessibility and convenience. The limitation is that your provider may also be handling hair loss, sexual health, and dermatology cases alongside your weight management, which can dilute specialization.

Henry Meds' Provider Approach

Henry Meds uses asynchronous telehealth consultations as its primary model. Patients complete an intake form, a provider reviews it, and a prescription is issued if clinically appropriate. Video consultations are more limited compared to Ro. Follow-up support is messaging-based. Henry Meds charges a separate consultation fee, which raises the question of whether patients receive proportionally more provider attention for that added cost. Patient reviews suggest the clinical experience is functional but not deeply personalized. For a detailed look at patient-reported experiences, see our guide on Henry Meds side effects.

Why Specialization Matters for GLP-1 Treatment

GLP-1 dose titration is not a one-size-fits-all process. Optimal results require individualized adjustments based on tolerance, side effect profile, metabolic response, and patient goals. Research from the SELECT cardiovascular outcomes trial (Lincoff et al., New England Journal of Medicine, 2023) further demonstrated the importance of proper GLP-1 management, showing cardiovascular benefits that depend on sustained, well-managed treatment. Generalist providers who handle dozens of health categories may follow standard protocols without the nuanced adjustments that a metabolic health specialist would make. Trimi's dedicated weight management providers handle GLP-1 therapy exclusively, which supports more individualized care.

Where Ro Has the Advantage

In a fair comparison, Ro holds meaningful advantages over Henry Meds in several categories that matter to patients making a provider decision.

For patients who have had a positive experience with Ro in other health categories and value platform familiarity, staying within the Ro ecosystem for weight loss is reasonable. Patients interested in Ro's specific weight loss track record should review our detailed Ro semaglutide review for 2026.

Where Henry Meds Has the Advantage

Henry Meds brings its own strengths to the comparison, particularly for patients with specific priorities.

Where Both Ro and Henry Meds Fall Short

Despite their respective strengths, both Ro and Henry Meds share structural limitations that stem from their generalist business models. These are not criticisms unique to either platform — they reflect the inherent tradeoffs of operating a multi-category telehealth company in a specialized medical niche.

Patients who have experienced these limitations firsthand often look for alternatives. Our guides on canceling Ro and switching providers and canceling Henry Meds and switching providers walk through the transition process step by step.

Clinical Evidence Behind GLP-1 Weight Loss

Regardless of which provider you choose, the medications prescribed by Ro, Henry Meds, and Trimi are backed by robust clinical evidence. Understanding this evidence helps patients set realistic expectations and evaluate whether the clinical support they receive from their provider is adequate for achieving those outcomes.

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) randomized 1,961 adults with obesity or overweight to weekly semaglutide 2.4 mg or placebo for 68 weeks. The semaglutide group achieved a mean weight loss of 14.9 percent of body weight compared to 2.4 percent with placebo. More than one-third of participants lost 20 percent or more of their body weight. These results established semaglutide as the most effective single-agent GLP-1 medication available at the time.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) randomized 2,539 adults to tirzepatide at doses of 5 mg, 10 mg, or 15 mg weekly versus placebo for 72 weeks. The highest dose group achieved a mean weight loss of 22.5 percent of body weight. More than half of participants on the 15 mg dose lost 20 percent or more of their body weight, demonstrating tirzepatide's superiority to semaglutide in head-to-head efficacy comparisons.

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) added cardiovascular outcome data, demonstrating that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20 percent in adults with overweight or obesity and established cardiovascular disease. This trial enrolled 17,604 participants and followed them for a mean of 39.8 months, providing the strongest evidence to date that GLP-1 weight loss therapy produces benefits beyond the scale.

These trials were conducted with brand-name formulations under strictly controlled conditions. Compounded versions prescribed by Ro, Henry Meds, and Trimi contain the same active ingredients but have not been independently studied in separate clinical trials. This is standard for compounded medications and does not indicate reduced efficacy, but patients should understand the distinction. For detailed side effect information specific to these providers, see our guides on Ro weight loss side effects and Henry Meds side effects.

The Bottom Line: Ro vs Henry Meds vs Trimi

In a direct Ro vs Henry Meds comparison, Ro is the stronger option for most patients. Ro offers more competitive pricing for semaglutide, includes consultations in the plan price, operates its own pharmacy for better quality control, and provides optional video consultations. Henry Meds' separate consultation fees and higher medication prices make it the more expensive choice for comparable treatment, though its simpler platform and streamlined enrollment process may appeal to certain patients.

However, framing the decision as a binary choice between two generalist platforms overlooks a significant portion of the market. Specialized weight management providers like Trimi offer compounded semaglutide at $99 per month and tirzepatide at $125 per month — substantially less than either Ro or Henry Meds — with dedicated metabolic health providers, no contracts, no consultation fees, and delivery in 5 to 7 days.

The best provider for you depends on what you prioritize. If you value an established platform with integrated pharmacy operations, Ro is a solid choice. If you want a streamlined enrollment experience and are willing to pay a premium for it, Henry Meds serves that niche. If your primary goal is effective, affordable weight loss with specialized clinical support and no contractual commitments, Trimi is designed specifically for that purpose.

Before committing to any provider, calculate your total projected cost over 6 to 12 months including all fees, evaluate the depth of clinical support available for your specific needs, and confirm medication availability in your state. Your decision should be driven by which provider gives you the best chance of sustained, long-term weight loss success.